Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGIR | P43119 | 7/20 | 0.49 |
| ▸ | ADRA2A | P08913 | 5/20 | 0.48 |
| ▸ | GPR65 | Q8IYL9 | 1/20 | 0.48 |
| ▸ | ADRA2B | P18089 | 4/20 | 0.48 |
| ▸ | ADRA2C | P18825 | 4/20 | 0.48 |
| ▸ | ITGB3 | P05106 | 3/20 | 0.45 |
| ▸ | ITGAV | P06756 | 3/20 | 0.45 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.45 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.42 |
| ▸ | ITGB5 | P18084 | 2/20 | 0.42 |
| ▸ | F12 | P00748 | 1/20 | 0.42 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.42 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.42 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2836221 | 0.94 | ITGB3 (0.49) | PTGIRADRA2AGPR65ADRA2BADRA2C | |
| SCHEMBL2837795 | 0.92 | PTGIR (0.46) | PTGIRADRA2AGPR65ADRA2BADRA2C | |
| SCHEMBL2832066 | 0.92 | ITGB3 (0.48) | PTGIRADRA2AGPR65ADRA2BADRA2C | |
| SCHEMBL2841214 | 0.91 | ITGB3 (0.56) | ITGB3ITGAVITGA2BITGB1ITGB5 | |
| SCHEMBL2838710 | 0.88 | ADRA2A (0.47) | PTGIRADRA2AGPR65ADRA2BADRA2C | |
| SCHEMBL2838085 | 0.87 | ITGB3 (0.46) | PTGIRADRA2AGPR65ITGB3ITGAV | |
| SCHEMBL2833536 | 0.87 | ITGB3 (0.55) | ITGB3ITGAVITGA2BITGB1ITGB5 | |
| SCHEMBL2841479 | 0.86 | ITGB3 (0.60) | ITGB3ITGAVITGA2BITGB1ITGB5 | |
| SCHEMBL2837241 | 0.84 | ITGB3 (0.54) | ITGB3ITGAVITGA2BITGB1ITGB5 | |
| SCHEMBL2838049 | 0.84 | ITGB3 (0.48) | PTGIRADRA2AADRA2BADRA2CITGB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030144311-A1 | Propanoic acid derivatives as intergrin receptor antagonists | PHARMACIA ITALIA S.P.A. (IT) | 2003-07-31 | — | — | US | claimed |
| EP-1282602-A1 | PROPANOIC ACID DERIVATIVES AS INTEGRIN RECEPTOR ANTAGONISTS | Pharmacia Italia S.p.A. (IT) | 2003-02-12 | — | — | EP | claimed |
| WO-2001087840-A1 | PROPANOIC ACID DERIVATIVES AS INTEGRIN RECEPTOR ANTAGONISTS | PHARMACIA ITALIA S.P.A. (IT) | 2001-11-22 | — | — | WO | claimed |
| US-20180344803-A1 | Methods and Compositions For the Treatment of Proteinuric Diseases | THE GENERAL HOSPITAL CORPORATION | 2018-12-06 | — | — | US | disclosed |
| US-20160296592-A1 | Methods and Compositions for the Treatment of Proteinuric Diseases | THE GENERAL HOSPITAL CORPORATION | 2016-10-13 | — | — | US | disclosed |
| US-9345739-B2 | Methods and compositions for the treatment of proteinuric diseases | THE GENERAL HOSPITAL CORPORATION (US) | 2016-05-24 | — | — | US | disclosed |
| US-20100297139-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PROTEINURIC DISEASES | THE GENERAL HOSPITAL CORPORATION | 2010-11-25 | — | — | US | disclosed |
| US-6974828-B2 | Propanoic acid derivatives as intergrin receptor antagonists | PHARMACIA ITALIA S.P.A. (IT) | 2005-12-13 | — | — | US | disclosed |
| EP-1282602-B1 | PROPANOIC ACID DERIVATIVES AS INTEGRIN RECEPTOR ANTAGONISTS | PHARMACIA ITALIA SPA (IT) | 2005-09-21 | — | — | EP | disclosed |
| US-20030144311-A1 | Propanoic acid derivatives as intergrin receptor antagonists | PHARMACIA ITALIA S.P.A. (IT) | 2003-07-31 | — | — | US | disclosed |
| EP-1282602-A1 | PROPANOIC ACID DERIVATIVES AS INTEGRIN RECEPTOR ANTAGONISTS | Pharmacia Italia S.p.A. (IT) | 2003-02-12 | — | — | EP | disclosed |
| WO-2001087840-A1 | PROPANOIC ACID DERIVATIVES AS INTEGRIN RECEPTOR ANTAGONISTS | PHARMACIA ITALIA S.P.A. (IT) | 2001-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160296592-A1 | Methods and Compositions for the Treatment of Proteinuric Diseases | ITGB3, PLAUR, PROC | PTGIR 1584/4885ADRA2A 2593/4885GPR65 1064/4885 |
| US-20180344803-A1 | Methods and Compositions For the Treatment of Proteinuric Diseases | ITGB3, PLAUR, PROC | PTGIR 1584/4885ADRA2A 2593/4885GPR65 1064/4885 |
| US-20100297139-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PROTEINURIC DISEASES | ITGB3, PLAUR, PROC | PTGIR 1584/4885ADRA2A 2593/4885GPR65 1064/4885 |
| US-20030144311-A1 | Propanoic acid derivatives as intergrin receptor antagonists | ITGB3, HCAR3, ADRB3 | PTGIR 39/4885ADRA2A 203/4885GPR65 69/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.